Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia

Lonza and Genetix Biotherapeutics agreed that Lonza will expand capacity to support the manufacture of Genetix’s ZYNTEGLO, the only FDA-approved gene therapy for pediatric and adult patients with transfusion-dependent beta-thalassemia.

The collaboration began in 2013, and ZYNTEGLO received FDA approval in 2022.

Under the renewed agreement, commercial manufacturing for Genetix will continue at Lonza’s Houston, TX facility, a dedicated cell and gene therapy site. The collaboration also makes provisions to scale up manufacturing in the future for additional Genetix therapies, according to Daniel Palmacci, head of specialized modalities at Lonza.

“Our long-standing partnership with Lonza reflects our shared commitment to commercial excellence and operational discipline to bring curative therapies to patients impacted by rare disease,” said Brian Riley, president and CTO at Genetix. “Their scientific rigor, quality focus and consistent execution have been important in enabling a reliable supply of ZYNTEGLO. In the last year, patient demand for Genetix’s therapies has grown consistently and rapidly. Extending the agreement with Lonza and expanding capacity provides a strong foundation as we invest to meet the growing patient demand and broaden our long-term manufacturing strategy.”

The post Lonza Expands Agreement to Manufacture Gene Therapy for Transfusion-Dependent Beta-Thalassemia appeared first on GEN - Genetic Engineering and Biotechnology News.